



# ISLHD CARDIOVASCULAR CLINICAL TRIALS

**Illawarra Heart Health Centre**  
**May 2025**

## ISLHD CARDIOVASCULAR CLINICAL TRIALS UNIT

**Illawarra Heart  
Health Centre**

**Wollongong Hospital  
Loftus Street  
Wollongong NSW 2500**

**Ph 02 4253 4908  
Fax 02 4253 4950**

### **Team**

**A/Prof Astin Lee** Director of Cardiology  
**Stephen Mackay** Trial Lead  
**Martin Walker** Trial Coordinator  
**Shaunagh Napier** Research Officer

The Illawarra Shoalhaven Local Health District (ISLHD) Cardiovascular Clinical Trials Unit is situated at the Illawarra Heart Health Centre in Wollongong Hospital. It boasts a specialised team comprising doctors, nurses, and allied health professionals.

This unit actively supports a range of clinical trials, contributing to evidence-based practices, fostering knowledge development and enhancing patient care within the local community.

## **CONGRATULATIONS TEAM**

Our Wollongong Cardiology Trials Team were successful in recruiting the very **FIRST AUSTRALIAN PARTICIPANT** into the SOS-AMI Study.

Anyone at risk of having an Acute Myocardial Infarction requires early intervention. The first rule of cardiac intervention is "Treatment Within the Golden Hour!"

The SOS-AMI study recruits participants that are at risk of having an AMI. Study participants are required to self inject (a bit like an EpiPen) at the first signs of heart attack prior to emergency services care.



## **REFERRAL OR CONSULTATION**






To discuss your patient with an ISLHD Trials Clinician, please phone  
Illawarra Heart Health Centre on 02 4253 4908 or  
**Email: [ISLHD-cardiacresearch@health.nsw.gov.au](mailto:ISLHD-cardiacresearch@health.nsw.gov.au)**

# ISLHD Cardiovascular Clinical Trials


**\*\*CURRENTLY OPEN FOR RECRUITMENT\*\***

*Scan the QR Code for more information including eligibility criteria*

## Medication trials

<b>Heart Failure &amp; Inflammation</b>	<b>ATHENA:</b> Ziltivekimab (anti-inflammatory monoclonal antibody) versus placebo in patients with heart failure, mildly reduced ejection fraction HFmrEF, or preserved ejection fraction HFpEF. Evaluating functional capacity, heart failure symptoms and systemic inflammation. 4 x Monthly injection	A/Prof Lee	
<b>Acute Myocardial Infarct</b>	<b>ARTEMIS:</b> Ziltivekimab (anti-inflammatory monoclonal antibody) versus placebo on patients with acute myocardial infarct CV outcome study. Monthly injections	A/Prof Lee	
<b>Acute Coronary Syndrome</b>	<b>LIBREXIA:</b> Milvexian (Factor Xia inhibitor) versus placebo in patients after a recent acute coronary syndrome. Investigating the efficacy and safety. Oral tablet taken twice a day.	A/Prof Lee	
<b>Acute Myocardial Infarct</b>	<b>SOS-AMI:</b> Self-administered selatogrel (or placebo) injection for prevention and treatment of acute myocardial infarction in participants with a recent history of acute myocardial infarction. Self administered injection only if and when required.	A/Prof Lee	
<b>Pulmonary Hypertension</b>	<b>APEX:</b> TX000045 (a relaxin-like compound) versus placebo in patients with pulmonary hypertension secondary to heart failure. Investigating safety and effectiveness of TX000045. Injections every 2 weeks.	Dr Moragues	

## Intervention trials

<b>Aortic stenosis</b>	<b>EASY-AS:</b> A trial of early valve replacement in severe asymptomatic aortic stenosis	Dr Danson	
<b>Hyperlipidaemia</b>	<b>GOAL ASIA:</b> Guideline Oriented Approach to Lipid Lowering In Asia-Pacific	A/Prof Lee	
<b>LV thrombus</b>	<b>RELEVANT:</b> Resolution of left ventricular thrombus with different anti coagulation strategies	Dr Moragues	
<b>Implant device</b>	<b>PROTECT ICD:</b> Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias following Acute Myocardial Infarction	A/Prof Lee	
<b>Pacemakers</b>	<b>PARTICIPATE:</b> Partnering remote monitoring of implanted cardiac devices with intelligent patient engagement	A/Prof Lee	

**For further information regarding these trials at the Illawarra Heart Health Centre contact:**  
**Stephen Mackay (Trial Lead)** 02 4253 4624; **Martin Walker (Trial Coordinator)** 02 4253 4650  
 email [ISLHD-cardiacresearch@health.nsw.gov.au](mailto:ISLHD-cardiacresearch@health.nsw.gov.au)